However, diuretics, mineralocorticoid antagonists, and sodium–glucose cotransporter 2 (SGLT2) inhibitors have all been found to be well tolerated, and their use is likely beneficial in the management of patients with ATTR-CM. This evidence concerns the gene SLC5A2 and cutaneous mastocytosis.